2022.03.15
I-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act
I-Mab today provides updates on the recent development relating to the HFCAA and its implementation.
2022.03.09
I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting
I-Mab today announced that two poster presentations featuring translational research data of enoblituzumab and preclinical data of TJ-C64B will be presented at AACR 2022.
2022.03.03
I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer
I-Mab today announced that the U.S. FDA has granted Orphan Drug Designation for TJ-CD4B for the treatment of gastric cancer including cancer of gastroesophageal junction.
2022.01.28
I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs
I-Mab announced the signing of a partnership agreement with the Hangzhou Qiantang New Area in China to manufacture its innovative drugs locally and accelerate its transition to commercialization.
2022.01.18
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors
I-Mab today announced that the first patient has been dosed in its China phase 2 trial of lemzoparlimab in combination with the PD-1 antibody toripalimab in patients with advanced solid tumors.
2022.01.14
I-Mab Announces Execution of Senior Management Team Share Purchase Plan
The senior management team of the Company have executed the share purchase plan with the open market purchase of 70,000 of the Company’s ADS in an aggregate amount of over US$2.6 million as of 14 Jan, 2022.
2022.01.12
I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors
I-Mab today announced that the first patient had been dosed in its China phase 2 study of efineptakin alfa in combination with pembrolizumab in patients with advanced solid tumors.
2022.01.06
I-Mab Announces Senior Management Team Share Purchase Plan
I-Mab today announced that the senior management team have informed the Company of their intention to use their personal funds to purchase the Company's American depositary shares on the open market for an aggregate amount of minimum US$3 million and up to US$20 million no later than February 28, 20...
2021.12.31
I-Mab Announces Upcoming Participation at January Conferences
I-Mab today announced its participation in the following conferences in January 2022.
2021.12.27
I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
I-Mab announced that the CDE of China’s NMPA has approved I-Mab’s IND submission for the initiation of a phase 2 trial in China for enoblituzumabin combination with pembrolizumab in patients with solid tumors, including non-small cell lung cancer, urothelial carcinoma, and other selected cancers.